Production (Stage)
Travere Therapeutics, Inc.
TVTX
$15.84
$0.140.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 75.65% | 60.55% | 57.08% | 47.42% | 69.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 75.65% | 60.55% | 57.08% | 47.42% | 69.52% |
| Cost of Revenue | -7.82% | -12.17% | -10.42% | -5.64% | 4.14% |
| Gross Profit | 153.34% | 107.14% | 82.33% | 56.00% | 37.73% |
| SG&A Expenses | 3.38% | -0.54% | -0.32% | 6.87% | 21.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.02% | -6.25% | -5.29% | 0.56% | 12.58% |
| Operating Income | 36.26% | 32.00% | 26.52% | 14.67% | 1.94% |
| Income Before Tax | 45.61% | 14.78% | 6.55% | -4.14% | -18.10% |
| Income Tax Expenses | -109.52% | -46.19% | 19.27% | 1.42% | -0.88% |
| Earnings from Continuing Operations | 45.66% | 14.80% | 6.54% | -4.14% | -18.08% |
| Earnings from Discontinued Operations | -100.32% | -100.35% | -100.87% | 290.98% | 472.74% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.70% | -188.64% | -303.74% | 52.54% | 44.22% |
| EBIT | 36.26% | 32.00% | 26.52% | 14.67% | 1.94% |
| EBITDA | 42.64% | 37.13% | 30.85% | 18.66% | 5.80% |
| EPS Basic | -33.93% | -156.92% | -215.81% | 58.36% | 52.74% |
| Normalized Basic EPS | 37.52% | 34.87% | 33.19% | 26.30% | 20.19% |
| EPS Diluted | -33.93% | -156.92% | -215.81% | 58.36% | 52.74% |
| Normalized Diluted EPS | 37.52% | 34.87% | 33.19% | 26.30% | 20.19% |
| Average Basic Shares Outstanding | 6.81% | 6.25% | 8.50% | 12.85% | 17.75% |
| Average Diluted Shares Outstanding | 6.81% | 6.25% | 8.50% | 12.85% | 17.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |